Brief: Mira Pharmaceuticals Announces Approval And Initiation Of Phase 1 Clinical Trial For Ketamir-2 In Neuropathic Pain
04/03/2025 14:14
March 4 (Reuters) - Mira Pharmaceuticals Inc MIRA.O: MIRA PHARMACEUTICALS ANNOUNCES APPROVAL AND INITIATION OF PHASE 1 CLINICAL TRIAL FOR KETAMIR-2 IN NEUROPATHIC PAIN Source text: [ID:n0001493152-25-008977] Further company coverage: MIRA.O (Reuters.Briefs@thomsonreuters.com)
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing